While pathological complete response (pCR) serves as a less established surrogate for long-term survival in HR+/HER2- breast cancer compared to other subtypes, it still helps to identify patients at a higher risk of relapse and can be used [21, 22, 139]. This evidence concerns the gene ERBB2 and breast cancer.